Patents Assigned to ADLAI NORTYE BIOPHARMA CO., LTD.
  • CYCLIN K DEGRADER
    Publication number: 20240368147
    Abstract: The disclosure provides a compound of formula (I) and pharmaceutical compositions thereof. The compound of formula (I) of the present disclosure can be used as a degradation agent of cyclin K (CyclinK protein), and can be used to prevent or treat diseases related to CyclinK protein.
    Type: Application
    Filed: August 25, 2022
    Publication date: November 7, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Beidi XU, Qingchong QIU, Zhiyong YU, Nanhai HE, Bin JI, Ling ZHANG, Xiaohan WANG, Xiangyu XIA, Zhao SUN
  • PD-L1 antagonist compound
    Patent number: 12091398
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 17, 2024
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan Li, Beidi Xu, Qiaodong Wen, Enguang Feng, Ji Wang, Yang Lu, Yu Zhou, Zhiyong Yu, Zhiying Huang
  • HIGH ACTIVITY STING PROTEIN AGONIST
    Publication number: 20240287093
    Abstract: The present disclosure provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using compounds of Formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: August 21, 2019
    Publication date: August 29, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Yufeng CHEN, Kaixuan CHEN, Pan LI, Canfeng LIU, Ji WANG, Qingchong QIU, Yang LU
  • COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER
    Publication number: 20240285640
    Abstract: A combination therapy for treating PIK3CA-mutated cancer, comprising administering a PI3K inhibitor, a prostaglandin receptor (PGE2) inhibitor, and a PD-1 inhibitor to a subject in need thereof. The anti-tumor activity brought about by a three-drug combination method is significantly superior to that brought about by a two-drug combination method of the PI3K inhibitor and the PD-1 inhibitor, and the prostaglandin receptor (PGE2) and the PD-1 inhibitor.
    Type: Application
    Filed: November 30, 2021
    Publication date: August 29, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Nanhai HE, Peng CHEN, Zhiyong YU, Yang LU
  • HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND
    Publication number: 20240189320
    Abstract: The present invention provides compounds of Formula (I) or (II), pharmaceutical compositions thereof, and methods of using compounds of Formula (I) or (II) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: August 22, 2019
    Publication date: June 13, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Yufeng CHEN, Kaixuan CHEN, Pan LI, Canfeng LIU, Ji WANG, Qingchong QIU, Yang LU
  • System and method for screening and assessing agents for tumor immunotherapy
    Patent number: 11965875
    Abstract: The present application relates to a system and a method for effectively screening and assessing agents for tumor immunotherapy, which includes assessment for the effects of target cells, non-target cells, and tumor infiltration. The system and method of the present application can be used to comprehensively and systematically assess the effectiveness and safety of the agent against tumor immune cells.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: April 23, 2024
    Assignee: ADLAI NORTYE BIOPHARMA CO. LTD.
    Inventors: Nanhai He, Youping Wang, Yang Lu, Donghui Yang
  • BIOMARKER AND APPLICATION THEREOF
    Publication number: 20240085425
    Abstract: The present disclosure provides an application of non-phosphorylated ?-catenin protein in tumor cells as a biomarker for predicting the responsivity or sensitivity of tumor cells to wnt pathway inhibitors, a method of using non-phosphorylated ?-catenin protein in tumor cells as a biomarker to predict the responsivity or sensitivity of tumor cells to wnt pathway inhibitors, a method for treating tumor patients, a method for detecting the content of non-phosphorylated ?-catenin in tumor tissues or tumor cells, and a suitable wnt inhibitor.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 14, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Nanhai HE, Youping WANG, Zhihong LIU, Yufeng CHEN
  • ANTI-TNFR2 ANTIBODY AND APPLICATION THEREOF
    Publication number: 20240043551
    Abstract: Provided is an antibody or an antigen binding fragment thereof capable of specifically binding to Tumor necrosis factor receptor type 2, which comprises a VH, a VL or both, said VH comprises at least one HCDR, which comprises an amino acid sequence selected from the group consisting of the amino acid sequences as set forth in SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17. The antibody or an antigen binding fragment thereof binds strongly and specifically to TNFR2.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 8, 2024
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Yi ZHANG, Yonglin CHEN
  • HIGH ACTIVITY HPK1 KINASE INHIBITOR
    Publication number: 20230399327
    Abstract: A compound of formula (I) having the activity of inhibiting HPK1 kinase and a pharmaceutical composition comprising the compound. Also provided are the use of the compound in the prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 14, 2023
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Yufeng CHEN, Canfeng LIU, Meng LV, Qiaodong WEN, Yongqiang SHI, Peng WU, Kaixuan CHEN, Han YANG, Wanli CHENG, Youping WANG, Pingping LU, Nanhai HE
  • HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
    Publication number: 20230390301
    Abstract: Provided are a compound having the structure of formula (I) for inhibiting Wnt pathway activity, a pharmaceutical composition comprising the compound, and use of the compound in prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases, or immune-mediated diseases.
    Type: Application
    Filed: October 27, 2021
    Publication date: December 7, 2023
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Yufeng CHEN, Peng WU, Meng LV, Canfeng LIU, Han YANG, Kaixuan CHEN, Wanli CHENG, Feifan LI, Youping WANG, Keke CHEN, Pingping LU, Nanhai HE
  • Construction of fully human antibody yeast display technique
    Patent number: 11680271
    Abstract: The present disclosure application relates to a construction method of a yeast display library (YSD), specifically to a construct for a yeast display library, an expression vector, a host cell and a construction method and use thereof. The yeast display library provided by the present application has high transformation efficiency and rich diversity.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: June 20, 2023
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Nanhai He, Dandan Chen, Yang Lu, Donghui Yang
  • PD-L1 ANTAGONIST COMPOUND
    Publication number: 20230054028
    Abstract: Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 23, 2023
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Zhiyong YU, Pan LI, Beidi XU, Yu ZHOU, Wei PANG, Qiaodong WEN, Yongqiang SHI, Zhao SUN, Meng LV
  • PD-L1 ANTAGONIST COMPOUND
    Publication number: 20220227733
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 21, 2022
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan LI, Beidi XU, Qiaodong WEN, Enguang FENG, Ji WANG, Yang LU, Yu ZHOU, Zhiyong YU, Zhiying HUANG
  • Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine
    Patent number: 11111230
    Abstract: The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 7, 2021
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan Li, Qiaodong Wen, Ji Wang, Quan Gan, Yang Lu, Donghui Yang
  • HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND
    Publication number: 20200399265
    Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 24, 2020
    Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Shifeng LIU, Zhiyong YU, Wei PANG, Ji WANG, Peng CHEN